BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28695235)

  • 1. Preoperative CT in patients with surgically resectable pancreatic adenocarcinoma: does the time interval between CT and surgery affect survival?
    Healy GM; Redmond CE; Murphy S; Fleming H; Haughey A; Kavanagh R; Swan N; Conlon KC; Malone DE; Ryan ER
    Abdom Radiol (NY); 2018 Mar; 43(3):620-628. PubMed ID: 28695235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.
    Mellon EA; Jin WH; Frakes JM; Centeno BA; Strom TJ; Springett GM; Malafa MP; Shridhar R; Hodul PJ; Hoffe SE
    Acta Oncol; 2017 Mar; 56(3):391-397. PubMed ID: 27885876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural history of preoperative subcentimeter pulmonary nodules in patients with resectable pancreatic adenocarcinoma: a retrospective cohort study.
    Chang ST; Nguyen DC; Raptis C; Menias CO; Zhou G; Wang-Gillam A; Linehan DC; Hawkins WG; Strasberg SM; Fields RC
    Ann Surg; 2015 May; 261(5):970-5. PubMed ID: 24950261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reassessment of the clinical significance of portal-superior mesenteric vein invasion in borderline resectable pancreatic cancer.
    Hoshimoto S; Hishinuma S; Shirakawa H; Tomikawa M; Ozawa I; Wakamatsu S; Hoshi S; Hoshi N; Hirabayashi K; Ogata Y
    Eur J Surg Oncol; 2017 Jun; 43(6):1068-1075. PubMed ID: 28427822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective.
    Picozzi VJ; Oh SY; Edwards A; Mandelson MT; Dorer R; Rocha FG; Alseidi A; Biehl T; Traverso LW; Helton WS; Kozarek RA
    Ann Surg Oncol; 2017 Jun; 24(6):1722-1730. PubMed ID: 28054192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the surgical waiting list affect pathological and survival outcome in resectable pancreatic ductal adenocarcinoma?
    Marchegiani G; Andrianello S; Perri G; Secchettin E; Maggino L; Malleo G; Bassi C; Salvia R
    HPB (Oxford); 2018 May; 20(5):411-417. PubMed ID: 29191689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
    Papalezova KT; Tyler DS; Blazer DG; Clary BM; Czito BG; Hurwitz HI; Uronis HE; Pappas TN; Willett CG; White RR
    J Surg Oncol; 2012 Jul; 106(1):111-8. PubMed ID: 22311829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
    Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
    Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative assessment of the resectability of pancreatic ductal adenocarcinoma on CT according to the NCCN Guidelines focusing on SMA/SMV branch invasion.
    Park SJ; Jang S; Han JK; Kim H; Kwon W; Jang JY; Lee KB; Kim H; Lee DH
    Eur Radiol; 2021 Sep; 31(9):6889-6897. PubMed ID: 33740095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating Recurrence after Upfront Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma by Using Pancreatic CT: Development and Validation of a Risk Score.
    Kim DW; Lee SS; Kim SO; Kim JH; Kim HJ; Byun JH; Yoo C; Kim KP; Song KB; Kim SC
    Radiology; 2020 Sep; 296(3):541-551. PubMed ID: 32662759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic adenocarcinoma: quantitative CT features are correlated with fibrous stromal fraction and help predict outcome after resection.
    Cai X; Gao F; Qi Y; Lan G; Zhang X; Ji R; Xu Y; Liu C; Shi Y
    Eur Radiol; 2020 Sep; 30(9):5158-5169. PubMed ID: 32346792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
    Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
    Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic adenocarcinoma: A simple CT score for predicting margin-positive resection in patients with resectable disease.
    Cassinotto C; Dohan A; Zogopoulos G; Chiche L; Laurent C; Sa-Cunha A; Cuggia A; Reinhold C; Gallix B
    Eur J Radiol; 2017 Oct; 95():33-38. PubMed ID: 28987689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis on the clinical therapeutic effects of arterial first approach pancreatoduodenectomy in the treatment of borderline resectable pancreatic adenocarcinoma].
    Jin G; Zheng KL; Guo SW; Shao Z; Liu C; Shi XH; Liu RD; Bai SJ; Jiang H; Bian Y; Hu XG
    Zhonghua Wai Ke Za Zhi; 2017 Dec; 55(12):909-915. PubMed ID: 29224265
    [No Abstract]   [Full Text] [Related]  

  • 16. Can a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved subsequent R0 resection?
    Guo Y; Czeyda-Pommersheim F; Miccio JA; Mahalingam S; Cecchini M; Pahade J
    Abdom Radiol (NY); 2021 Dec; 46(12):5609-5617. PubMed ID: 34557934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
    Kim NH; Kim HJ
    Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Impact of Time to Surgery in Patients With Resectable Pancreatic Ductal Adenocarcinoma.
    Joliat GR; Labgaa I; Gilgien J; Demartines N
    Pancreas; 2021 Jan; 50(1):104-110. PubMed ID: 33370031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study.
    Comito T; Cozzi L; Zerbi A; Franzese C; Clerici E; Tozzi A; Iftode C; Navarria P; D'Agostino G; Fogliata A; Mancosu P; Tomatis S; Carnaghi C; Personeni N; Santoro A; Scorsetti M
    Eur J Surg Oncol; 2017 Apr; 43(4):735-742. PubMed ID: 28131670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.